Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18804997rdf:typepubmed:Citationlld:pubmed
pubmed-article:18804997lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:18804997lifeskim:mentionsumls-concept:C0023449lld:lifeskim
pubmed-article:18804997lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:18804997lifeskim:mentionsumls-concept:C0205409lld:lifeskim
pubmed-article:18804997lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:18804997lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:18804997lifeskim:mentionsumls-concept:C1517060lld:lifeskim
pubmed-article:18804997lifeskim:mentionsumls-concept:C1709634lld:lifeskim
pubmed-article:18804997pubmed:issue16lld:pubmed
pubmed-article:18804997pubmed:dateCreated2008-10-30lld:pubmed
pubmed-article:18804997pubmed:abstractTextWe report on the efficiency of treatment of first isolated extramedullary relapse of B-cell precursor acute lymphoblastic leukaemia. Sixty-eight children and adolescents were included in the trial COPRALL-97. Stratification criteria were time to relapse: first complete remission duration of less than 24 months for group G3A (n=35), relapse beyond 24 months for group G3B (n=33). Treatment consisted of risk-adapted alternating short course multiagent systemic and intrathecal chemotherapy and irradiation (18Gy). Event free survival (EFS) and overall survival (OS) for all registered patients at 6 years were 43% and 55%, respectively. EFS at 4 years for patients of group G3A and G3B were, respectively, 31% and 61% (p=0.0071) while OS at 4 years were, respectively, 40% and 76% (p=0.065). Our analyses highlighted two independent risks factors predictive of decreased EFS: early relapse and age at the initial diagnosis above 6 years. Early central nervous system relapses have a bad prognosis, and new therapeutic strategies are needed.lld:pubmed
pubmed-article:18804997pubmed:languageenglld:pubmed
pubmed-article:18804997pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18804997pubmed:citationSubsetIMlld:pubmed
pubmed-article:18804997pubmed:statusMEDLINElld:pubmed
pubmed-article:18804997pubmed:monthNovlld:pubmed
pubmed-article:18804997pubmed:issn1879-0852lld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:BenoitYvesYlld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:MercierMariet...lld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:BordigoniPier...lld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:LevergerGuyGlld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:BaruchelAndré...lld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:MichelGérardGlld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:PlouvierEmman...lld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:BertrandYvesYlld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:DomenechCarin...lld:pubmed
pubmed-article:18804997pubmed:authorpubmed-author:PuraveauMarcMlld:pubmed
pubmed-article:18804997pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18804997pubmed:volume44lld:pubmed
pubmed-article:18804997pubmed:ownerNLMlld:pubmed
pubmed-article:18804997pubmed:authorsCompleteYlld:pubmed
pubmed-article:18804997pubmed:pagination2461-9lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:meshHeadingpubmed-meshheading:18804997...lld:pubmed
pubmed-article:18804997pubmed:year2008lld:pubmed
pubmed-article:18804997pubmed:articleTitleFirst isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study.lld:pubmed
pubmed-article:18804997pubmed:affiliationService d'Immuno-Hématologie Pédiatrique, Institut d'Hématologie et Oncologie Pédiatrique, Hospices Civils de Lyon, Université Claude Bernard Lyon1, Lyon Cedex 08, France. carine_halfon@yahoo.frlld:pubmed
pubmed-article:18804997pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18804997pubmed:publicationTypeMulticenter Studylld:pubmed